Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials. The company’s lead candidate – an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas – is targeting metastatic pancreatic cancer and has received Breakthrough Therapy designation from the US Food and Drug Administration.
NASDAQ ADRO (Common Stock) 0.21.79%)October 28, 20164:00 p.m. ET
October 23, 2016 Aduro Biotech to Host Conference Call
Events & Presentations
October 24, 2016Aduro Biotech Inc Corporate Conference Call
|Data Provided by Thomson Reuters|